December 8, 2025Blood

Clinical features and outcomes of myeloproliferative neoplasm patients with MPL mutations and concurrent JAK2/calr mutations

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Retrospective case series highlights thromboembolic events and prognosis in myeloproliferative neoplasm patients with MPL and CALR mutations.

To characterize clinical features of myeloproliferative neoplasm patients with MPL mutations alongside JAK2 or CALR mutations.
Conducted a retrospective case series at two cancer centers from 2010-2022.
Identified patients through next-generation sequencing for MPL mutations.
Collected data on demographics, disease characteristics, and treatment history.
Identified 11 patients with concurrent MPL and either JAK2 or CALR mutations.
Noted thromboembolic events in 2 patients post-diagnosis with myelofibrosis.
Median follow-up duration was 33 months, with some rare MPL variants impacting outcomes.

Gajjar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

December 8, 2025Blood

View Full Paper

Ask AI

Bookmark

Authors

Retrospective case series highlights thromboembolic events and prognosis in myeloproliferative neoplasm patients with MPL and CALR mutations.

To characterize clinical features of myeloproliferative neoplasm patients with MPL mutations alongside JAK2 or CALR mutations.
Conducted a retrospective case series at two cancer centers from 2010-2022.
Identified patients through next-generation sequencing for MPL mutations.
Collected data on demographics, disease characteristics, and treatment history.
Identified 11 patients with concurrent MPL and either JAK2 or CALR mutations.
Noted thromboembolic events in 2 patients post-diagnosis with myelofibrosis.
Median follow-up duration was 33 months, with some rare MPL variants impacting outcomes.

Gajjar et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark